Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mirum Pharmaceuticals (MIRM) Amortizatization of Intangibles (2020 - 2023)

Historic Amortizatization of Intangibles for Mirum Pharmaceuticals (MIRM) over the last 4 years, with Q4 2023 value amounting to $29000.0.

  • Mirum Pharmaceuticals' Amortizatization of Intangibles fell 9714.85% to $29000.0 in Q4 2023 from the same period last year, while for Dec 2023 it was $1.7 million, marking a year-over-year increase of 129.18%. This contributed to the annual value of $1.7 million for FY2023, which is 129.18% up from last year.
  • According to the latest figures from Q4 2023, Mirum Pharmaceuticals' Amortizatization of Intangibles is $29000.0, which was down 9714.85% from $234000.0 recorded in Q3 2023.
  • Over the past 5 years, Mirum Pharmaceuticals' Amortizatization of Intangibles peaked at $1.0 million during Q4 2022, and registered a low of -$148000.0 during Q4 2021.
  • Over the past 4 years, Mirum Pharmaceuticals' median Amortizatization of Intangibles value was $94500.0 (recorded in 2021), while the average stood at $242687.5.
  • Per our database at Business Quant, Mirum Pharmaceuticals' Amortizatization of Intangibles tumbled by 28500.0% in 2021 and then soared by 3155000.0% in 2023.
  • Over the past 4 years, Mirum Pharmaceuticals' Amortizatization of Intangibles (Quarter) stood at $80000.0 in 2020, then tumbled by 285.0% to -$148000.0 in 2021, then soared by 787.16% to $1.0 million in 2022, then plummeted by 97.15% to $29000.0 in 2023.
  • Its Amortizatization of Intangibles was $29000.0 in Q4 2023, compared to $234000.0 in Q3 2023 and $633000.0 in Q2 2023.